<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605237</url>
  </required_header>
  <id_info>
    <org_study_id>18-036/C</org_study_id>
    <nct_id>NCT04605237</nct_id>
  </id_info>
  <brief_title>Pancreatic Cancer Recurrence in the Netherlands</brief_title>
  <official_title>Detection, Treatment and Survival of Pancreatic Cancer Recurrence in the Netherlands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jeroen Bosch Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maasstad Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amphia Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onze Lieve Vrouwe Gasthuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reinier de Graaf Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Isala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this nationwide, observational cohort study is to evaluate current surveillance&#xD;
      strategies after primary resection of pancreatic ductal adenocarcinoma (PDAC) in the&#xD;
      Netherlands, with regard to the detection, treatment and survival of PDAC recurrence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of PDAC recurrence</measure>
    <time_frame>Within a follow-up period up to 5 years</time_frame>
    <description>Incidence of PDAC recurrence within the Netherlands; PDAC recurrence is either pathologically proven, or suspected through cross-sectional imaging, preferably confirmed by consensus during a multidisciplinary meeting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patterns of PDAC recurrence</measure>
    <time_frame>Within a follow-up period up to 5 years</time_frame>
    <description>Asymptomatic vs. symptomatic: Symptomatic recurrence is defined as the presence of symptoms suggestive for PDAC recurrence at recurrence diagnosis. If PDAC recurrence is detected in absence of suspected symptoms, disease recurrence was defined as asymptomatic.&#xD;
First site of recurrence: isolated local recurrence, liver-only, lung-only, multiple-site, other isolated distant&#xD;
Early vs. late recurrence: disease-free survival â‰¥12 months vs. &lt;12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment of PDAC recurrence</measure>
    <time_frame>Within a follow-up period up to 5 years</time_frame>
    <description>Either systemic and/or local treatment or best-supportive-care</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Within a follow-up period up to 5 years</time_frame>
    <description>Overall survival (from the time of resection), disease-free survival (from the time of resection), post-recurrence survival (from the time of recurrence diagnosis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of symptoms at time of (suspected) recurrence</measure>
    <time_frame>Within a follow-up period up to 5 years</time_frame>
    <description>Which symptoms are associated with PDAC recurrence?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance score at time of recurrence detection</measure>
    <time_frame>Within a follow-up period up to 5 years</time_frame>
    <description>What is the ECOG performance score of patients at time of recurrence diagnosis?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of imaging procedures during follow-up</measure>
    <time_frame>Within a follow-up period up to 5 years</time_frame>
    <description>How much imaging procedures are performed during postoperative follow-up for the detection of PDAC recurrence? Are these procedures routinely performed?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of histologically confirmed recurrences</measure>
    <time_frame>Within a follow-up period up to 5 years</time_frame>
    <description>How often is PDAC recurrence histologically confirmed?</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1750</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Pancreas Cancer</condition>
  <condition>PDAC</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients registered within the prospective, mandatory Dutch Pancreatic Cancer Audit who&#xD;
        underwent resection of histologically proven PDAC.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing a pancreatic resection (PPPD, Whipple, distal pancreatectomy or&#xD;
             total pancreatectomy) for histologically proven PDAC in one of the 16 Dutch centers&#xD;
             for pancreatic surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with 30-day postoperative mortality&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>I. Quintus Molenaar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iris van Goor, MD</last_name>
    <phone>+31631917882</phone>
    <email>I.W.J.vanGoor-5@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lois Daamen, MD</last_name>
    <phone>+31651223276</phone>
    <email>L.A.Daamen-3@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris van Goor, MD</last_name>
      <phone>+31631917882</phone>
      <email>I.W.J.vanGoor-5@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lois Daamen, MD</last_name>
      <phone>+31651223276</phone>
      <email>L.A.Daamen-3@umcutrecht.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>October 24, 2020</last_update_submitted>
  <last_update_submitted_qc>October 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Dr. I.Q. Molenaar</investigator_full_name>
    <investigator_title>Prof. dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT04605237/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

